The Most Significant Update to NICE Guidelines on Ovarian Cancer in 15 Years: What It Means for Patients and Clinicians.

In April 2026, the UK’s National Institute for Health and Care Excellence (NICE) introduced what has been described as the most significant update to ovarian cancer guidance in over 15 years. The changes, centred on the use of the CA125 blood test and referral pathways, represent a major shift in how clinicians identify and investigate suspected ovarian cancer, particularly in primary care settings.

Why this Update Matters

Ovarian cancer remains one of the most challenging cancers to diagnose early. Symptoms are often vague (bloating, abdominal discomfort, early satiety) and overlap with numerous benign conditions. As a result, many women are diagnosed at a later stage, when outcomes are poorer. Around 7,000 women are diagnosed each year in the UK, and there is still no effective national screening programme.

The previous NICE guidance, published in 2011 and updated in 2015, relied heavily on a single CA125 threshold of 35 IU/ml to determine whether further investigation or referral was needed.

The Key Change: Age-Specific CA125 Thresholds

Instead of a fixed cut-off, NICE now proposes age-based thresholds that reflect how ovarian cancer risk varies across the lifespan.

This change addresses two critical problems:

• Under-detection in older women: A fixed threshold may miss cancers in higher-risk, older populations.
• Over-investigation in younger women: The same threshold can trigger unnecessary referrals and anxiety in younger patients, where the test is less predictive.

By tailoring thresholds to age, the new guidance aims to improve diagnostic accuracy and ensure that those at highest risk are prioritised for urgent investigation.

A Shift for Younger Women: Moving Beyond CA125 Alone

One of the most striking elements of the update is the recognition that CA125 is less reliable in women under 40.

Under the new recommendations clinicians are advised not to rely solely on CA125 in younger women. For those with persistent or concerning symptoms, direct access to ultrasound imaging should be considered earlier in the pathway.

CA125 often acted as a gatekeeper test; now, clinical judgment and imaging play a more prominent role, particularly in younger populations.

Broader Referral Criteria and Earlier Investigation

The update also expands the criteria for urgent investigation. Notably for unexplained weight loss in women aged 60 and over is now highlighted as a trigger for urgent referral via cancer pathways.

Why This Is the Biggest Change in 15 Years

This update is being described as the most significant in over a decade not because it introduces a new drug or technology, but because it reshapes the diagnostic framework itself.

In essence, this is not a minor tweak, it is a redesign of how ovarian cancer is suspected and triaged at the front line of the NHS.

Implications for Practice

For general practitioners and frontline clinicians, the changes will require:

• Familiarity with new age-based CA125 thresholds
• Greater confidence in ordering imaging earlier, particularly for younger women
• Awareness of expanded symptom triggers for urgent referral

For patients, the update may lead to:

• Earlier investigations for concerning symptoms
• Fewer unnecessary referrals in low-risk groups
• Potentially earlier diagnosis, particularly in older women

Looking ahead

This update aligns with a broader trend in oncology: moving toward personalised risk assessment rather than rigid thresholds. It also highlights the limitations of current diagnostic tools and the need for continued innovation in early detection.

Whilst it is too early to measure the full impact, the hope is clear; a faster diagnosis, more accurate triage, and ultimately, improved survival outcomes for women with ovarian cancer.

If you feel that you or a loved one has suffered a misdiagnosis or a delay in diagnosis of cancer, please reach out to our Clinical Negligence Department who will be able to assist.